Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders

Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders

Abstract Background Aripiprazole (ARI) is the first-line treatment for tic disorders (TD). Cytochrome P450(CYP)2D6 (CYP2D6) and ATP-binding cassette, sub-family B, member 1 (ABCB1) transporter are involved in the metabolism of ARI. However, whether CYP2D6 and ABCB1 genetic polymorphisms influence cl...

Full description

Saved in:
Bibliographic Details
Main Authors: Yingying Xin, Liuliu Gao, Sichan Li, Jun Wang, Chen Chen, Yali Tuo, Gang Nie, Ruizhen Li, Dan Sun, Yongli Fu, Yang Wang, Zhisheng Liu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Pediatrics
Subjects:
CYP2D6
ABCB1
Aripiprazole
Pharmacokinetics
Tic disorders
Efficacy
Online Access:https://doi.org/10.1186/s12887-025-05856-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12887-025-05856-6

Similar Items